Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 19/20 | 0.56 |
| ▸ | NOS3 | P29474 | 18/20 | 0.56 |
| ▸ | NOS2 | P35228 | 12/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL499857 | 0.93 | NOS3 (0.64) | NOS1NOS3NOS2KDM4EMEN1 | |
| Hydrochloric Acid SCHEMBL499327 | 0.93 | NOS1 (0.63) | NOS1NOS3NOS2KDM4EMEN1 | |
| SCHEMBL499723 | 0.91 | NOS1 (0.64) | NOS1NOS3NOS2KDM4EMEN1 | |
| Hydrochloric Acid SCHEMBL500017 | 0.91 | NOS1 (0.63) | NOS1NOS3NOS2KDM4EMEN1 | |
| SCHEMBL4568000 | 0.89 | NOS3 (0.49) | NOS1NOS3NOS2KDM4EMEN1 | |
| SCHEMBL499616 | 0.89 | NOS3 (0.63) | NOS1NOS3NOS2KDM4EMEN1 | |
| Hydrochloric Acid SCHEMBL500020 | 0.89 | NOS3 (0.62) | NOS1NOS3NOS2KDM4EMEN1 | |
| SCHEMBL4567994 | 0.89 | NOS3 (0.49) | NOS1NOS3NOS2KDM4EMEN1 | |
| SCHEMBL499838 | 0.86 | NOS3 (0.57) | NOS1NOS3NOS2 | |
| Hydrochloric Acid SCHEMBL499547 | 0.85 | NOS1 (0.56) | NOS1NOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140163016-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2014-06-12 | — | — | US | disclosed |
| US-20120122855-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2012-05-17 | — | — | US | disclosed |
| US-8106043-B2 | Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2012-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122855-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | NOS1 2/4885NOS3 3/4885NOS2 1/4885 |
| US-20140163016-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | NOS1 2/4885NOS3 3/4885NOS2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.